BRPI0516974A - composição imunogênica compreendendo um polipeptìdeo; um método para induzir uma resposta imune contra staphylococcus epidermidis; um método para induzir uma resposta imune contra staphylococcus aureus; um método para a detecção e/ou identificação de staphylococcus epidermidis; um método para a detecção e/ou identificação de anticorpos para staphylococcus epidermidis - Google Patents

composição imunogênica compreendendo um polipeptìdeo; um método para induzir uma resposta imune contra staphylococcus epidermidis; um método para induzir uma resposta imune contra staphylococcus aureus; um método para a detecção e/ou identificação de staphylococcus epidermidis; um método para a detecção e/ou identificação de anticorpos para staphylococcus epidermidis

Info

Publication number
BRPI0516974A
BRPI0516974A BRPI0516974-7A BRPI0516974A BRPI0516974A BR PI0516974 A BRPI0516974 A BR PI0516974A BR PI0516974 A BRPI0516974 A BR PI0516974A BR PI0516974 A BRPI0516974 A BR PI0516974A
Authority
BR
Brazil
Prior art keywords
staphylococcus epidermidis
inducing
immune response
identification
detection
Prior art date
Application number
BRPI0516974-7A
Other languages
English (en)
Inventor
Bret Richard Sellman
Steven Morris Baker
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0516974A publication Critical patent/BRPI0516974A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

COMPOSIçãO IMUNOGêNICA COMPREENDENDO UM POLIPEPTìDEO; UM MéTODO PARA INDUZIR UMA RESPOSTA IMUNE CONTRA STAPHYLOCOCCUS EPIDERMIDIS; UM MéTODO PARA INDUZIR UMA RESPOSTA IMUNE CONTRA STAPHYLOCOCCUS AUREUS; UM MéTODO PARA A DETECçAO E/OU IDENTIFICAçAO DE STAPHYLOCOCCUS EPIDERMIDIS; UM MéTODO PARA A DETECçAO E/OU IDENTIFICAçAO DE ANTICORPOS PARA STAPHYLOCOCCUS EPIDERMIDIS. A presente invenção refere-se às composições imunogênicas, compreendendo polipeptideos isolados de Staphylococcus epidermidis. A invenção também se refere aos polinucleotídeos que codificam polipeptídeos de Staphylococcus epidermidis e seu uso em composições imunogênicas. Além disso, a invenção se refere a métodos de indução de uma resposta imune em mamíferos contra Staphylococcus epidermidis e Staphylococcus aureus usando composições imunogênicas de polipeptídeos e polinucleotídeos de Staphylococcus epidermidis. A invenção também se refere a métodos para a detecção de Staphylococcus epídermidis numa amostra biológica.
BRPI0516974-7A 2004-10-21 2005-10-19 composição imunogênica compreendendo um polipeptìdeo; um método para induzir uma resposta imune contra staphylococcus epidermidis; um método para induzir uma resposta imune contra staphylococcus aureus; um método para a detecção e/ou identificação de staphylococcus epidermidis; um método para a detecção e/ou identificação de anticorpos para staphylococcus epidermidis BRPI0516974A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62078804P 2004-10-21 2004-10-21
PCT/US2005/037746 WO2007001423A2 (en) 2004-10-21 2005-10-19 Immunogenic compositions of staphylococcus epidermidis polypeptide and polynucleotide antigens

Publications (1)

Publication Number Publication Date
BRPI0516974A true BRPI0516974A (pt) 2008-09-30

Family

ID=37595601

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516974-7A BRPI0516974A (pt) 2004-10-21 2005-10-19 composição imunogênica compreendendo um polipeptìdeo; um método para induzir uma resposta imune contra staphylococcus epidermidis; um método para induzir uma resposta imune contra staphylococcus aureus; um método para a detecção e/ou identificação de staphylococcus epidermidis; um método para a detecção e/ou identificação de anticorpos para staphylococcus epidermidis

Country Status (13)

Country Link
US (3) US8445000B2 (pt)
EP (4) EP1802335A2 (pt)
JP (2) JP2008517918A (pt)
KR (1) KR20070068455A (pt)
CN (1) CN101175508A (pt)
AR (1) AR051826A1 (pt)
AU (1) AU2005333603A1 (pt)
BR (1) BRPI0516974A (pt)
CA (1) CA2583121A1 (pt)
IL (1) IL182546A0 (pt)
TW (1) TW200619228A (pt)
WO (1) WO2007001423A2 (pt)
ZA (1) ZA200703274B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2468803B (en) * 2005-05-19 2011-01-19 Exocyte Ltd Screening methods for bacterial killing
NZ612315A (en) * 2009-04-14 2014-10-31 Novartis Ag Compositions for immunising against staphylococcus aureus
CN102481352A (zh) 2009-06-22 2012-05-30 惠氏有限责任公司 金黄色葡萄球菌抗原的免疫原性组合物
US20110200995A1 (en) * 2009-09-04 2011-08-18 Intelligent Medical Devices, Inc. Optimized probes and primers and methods of using same for the detection, screening, isolation and sequencing of vancomycin resistance genes and vancomycin resistant enterococci
AU2012280901B2 (en) * 2011-07-06 2016-11-10 Glaxosmithkline Biologicals S.A. Oil-in-water emulsions that contain nucleic acids
RU2649133C2 (ru) 2011-07-06 2018-03-29 Новартис Аг Катионные эмульсии масло-в-воде
CN104736165A (zh) * 2012-08-31 2015-06-24 诺华股份有限公司 用于针对金黄色葡萄球菌的免疫的稳定化的蛋白质
AU2015238512B2 (en) * 2014-03-26 2018-02-01 Glaxosmithkline Biologicals S.A. Mutant staphylococcal antigens
BR112019007796A2 (pt) * 2016-10-21 2019-09-03 Socpra Sciences Et Genie Sec construção de vacina e seus usos contra infecções causadas por staphylococcus
KR102838831B1 (ko) * 2019-01-30 2025-07-25 후지필름 일렉트로닉 머티리얼스 유.에스.에이., 아이엔씨. 컨테이너 및 이의 제조 방법
KR102627009B1 (ko) * 2021-12-17 2024-01-19 (주)메디톡스 피부 유해 세균에 대한 항세균 활성을 갖는 세균 균주, 및 이를 포함하는 약제학적 조성물

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4837151A (en) 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
ATE141646T1 (de) 1986-04-09 1996-09-15 Genzyme Corp Genetisch transformierte tiere, die ein gewünschtes protein in milch absondern
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
CA2123811C (en) * 1991-11-22 2005-07-05 Ali Ibrahim Fattom Type i and type ii surface antigens associated with staphylococcus epidermidis
WO1993013302A1 (de) 1991-12-23 1993-07-08 Michael Zoche Motor mit einer vorrichtung zur entölung
JP4124816B2 (ja) * 1992-03-19 2008-07-23 ヘンリー エム．ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン 通常のスタフィロコーカス抗原と反応する広い反応性のオプソニン抗体
WO1994016737A1 (en) * 1993-01-26 1994-08-04 Weiner David B Compositions and methods for delivery of genetic material
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
IL112820A0 (en) 1994-03-07 1995-05-26 Merck & Co Inc Coordinate in vivo gene expression
US6995008B1 (en) 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AU707298B2 (en) * 1994-09-21 1999-07-08 Henry M. Jackson Foundation For The Advancement Of Military Medicine Broadly reactive opsonic antibodies reactive with common staphylococcal antigens
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
WO1997014800A1 (en) 1995-10-16 1997-04-24 Smithkline Beecham Plc Novel saliva binding protein
US6168918B1 (en) 1996-01-31 2001-01-02 American Home Products Corp. Method of detecting foreign DNA integrated in eukaryotic chromosomes
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US7060458B1 (en) 1997-08-14 2006-06-13 Wyeth Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US6380370B1 (en) * 1997-08-14 2002-04-30 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
BR9913311A (pt) 1998-08-31 2001-10-16 Trinity College Dublin Molécula de ácido nucleico isolado, ácido nucleico isolado, vetor, proteìna, anticorpo e anti-soros formados contra uma proteìna, kit de diagnóstico, processos para reduzir a infecção de estafilococos coagulase-negativos de um dispositivo médico de retenção, para tratar uma infecção de estafilococus coagulase-negativa, para prevenir uma infecção de estafilococos coagulase-negativa em um paciente, para induzir uma resposta imunológica e para identificar compostos que inibem estafilococos coagulase-negativos
JP4673974B2 (ja) 1998-09-30 2011-04-20 ワイス・ホールディングズ・コーポレイション アジュバントとしての変異コレラホロトキシン
US6703492B1 (en) 1999-11-09 2004-03-09 Smithkline Beecham Corporation Staphylococcus epidermidis nucleic acids and proteins
WO2001034809A2 (en) * 1999-11-09 2001-05-17 Glaxo Group Limited Staphylococcus epidermidis nucleic acids and proteins
GB0014907D0 (en) * 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
US20020169288A1 (en) * 2001-03-15 2002-11-14 Magnus Hook Collagen-binding adhesin from staphylococcus epidermidis and method of use
IL159209A0 (en) 2001-06-07 2004-06-01 Wyeth Corp Mutant forms of cholera holotoxin as an adjuvant
CN1977971A (zh) 2001-06-07 2007-06-13 惠氏控股有限公司 作为佐剂的霍乱全毒素的突变体形式
CA2808598A1 (en) * 2001-08-02 2003-02-13 University Of Sheffield Antigenic polypeptides
MXPA05005045A (es) * 2002-11-12 2005-07-01 Brigham & Womens Hospital Vacuna de polisacarido para infecciones estafilococicas.
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
EP1608756B1 (en) * 2003-03-31 2009-11-18 Intercell AG Staphylococcus epidermidis antigens
EP2298340B1 (en) * 2004-09-22 2014-04-16 GlaxoSmithKline Biologicals S.A. Immunogenic composition for use in vaccination against staphylococcei
WO2006099747A1 (en) 2005-03-25 2006-09-28 National Research Council Of Canada Method for isolation of soluble polypeptides

Also Published As

Publication number Publication date
ZA200703274B (en) 2008-06-25
JP2008517918A (ja) 2008-05-29
US20130209501A1 (en) 2013-08-15
EP2298341A3 (en) 2011-07-13
TW200619228A (en) 2006-06-16
CA2583121A1 (en) 2007-01-04
EP2340848A2 (en) 2011-07-06
EP1802335A2 (en) 2007-07-04
EP2213298A3 (en) 2011-07-20
CN101175508A (zh) 2008-05-07
EP2298341A2 (en) 2011-03-23
IL182546A0 (en) 2008-12-29
AR051826A1 (es) 2007-02-14
US8445000B2 (en) 2013-05-21
JP2013121981A (ja) 2013-06-20
US20070292450A1 (en) 2007-12-20
EP2340848A3 (en) 2011-09-14
US20150196629A1 (en) 2015-07-16
WO2007001423A3 (en) 2007-11-15
EP2213298A2 (en) 2010-08-04
WO2007001423A2 (en) 2007-01-04
AU2005333603A1 (en) 2007-01-04
KR20070068455A (ko) 2007-06-29

Similar Documents

Publication Publication Date Title
BRPI0809926B8 (pt) composição que compreende antígenos de mycobacterium tuberculosis, polipeptídeo de fusão isolado, polinucleotídeo isolado que codifica o dito polipeptídeo e uso da dita composição para estimular uma resposta imune protetora
UY26783A1 (es) Antígenos de estreptococo.
BRPI0721003A2 (pt) Polinucleotídeo; vetor; célula recombinante; polipeptídeo; anticorpo; composição; composição preparada por um processo; uso da composição; método para preparar uma composição; método para preparar uma composição de anticorpo; método para induzir uma resposta imune em um mamífero; e método para prevenir ou tratar meningite bacteriana em um mamífero.
CY1118149T1 (el) Πρωτεϊνες και νουκλεϊνικα οξεα απο escherichia coli σχετιζομενο με μηνιγγιτιδα/σηψη
CL2019002250A1 (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco. (divisional solicitud 201803520)
BR112019011277A2 (pt) polinucleotídeo, sistema de expressão recombinante, vetor, polipeptídeo, célula recombinante, polipeptídeo de receptor imune sintético isolado ou heterodímero de polipeptídeo, célula efetora imune ou célula-tronco, população de células imunes ou efetoras, métodos de fabricação de uma célula efetora imune que expressa sir, de geração de uma população de células modificadas por rna, de fornecimento de imunidade antidoença e de tratamento ou prevenção de uma doença, composição, uso ou método, kit, e, sequência de aminoácidos.
BRPI0911385B8 (pt) polipeptídeo isolado, polipeptídeo de fusão, multímero e composição farmacêutica
BR112017020986A2 (pt) proteínas de ligação recombinantes e seu uso
Whiting et al. Characterisation of adsorbed anthrax vaccine by two-dimensional gel electrophoresis
GT200800132A (es) Anticuerpos anti-il-23 humanos, composiciones, metodos y usos
BR112017008108A2 (pt) incorporação de aminoácidos não naturais em proteínas
BR112012014801A8 (pt) uso combinado de proteínas cry1ca e cry1fa para controle de resistência a insetos
BR112018001572A2 (pt) método para induzir uma resposta imune, antígeno, adenovírus, uso de um antígeno e de um adenovírus, e, polinucleotídeo.
BR112018075653A2 (pt) anticorpos anti-b7-h3 e conjugados anticorpo fármaco
BR112015013183A2 (pt) proteínas de fusão para uso como aperfeiçoadores imunogênicos para indução de respostas de células t específicas para antígenos
BRPI0518994A2 (pt) anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas
BR0208874A (pt) Proteìnas superficiais de streptococcus pyogenes
BRPI0708344A8 (pt) Vetores adenovirais quiméricos e composição imunogênica
BRPI0508068A (pt) moléculas de ácido nucléico isoladas, vetor compreendendo as mesmas, polipeptìdeos isolados e composições compreendendo os mesmos
BR112015008036A2 (pt) população de peptídeos isolados, método para detectar em uma amostra um anticorpo, método para diagnosticar erliquiose monocítica e/ou granulocítica e kit
BR112021020777A2 (pt) Vacina de subunidade do csfv
BR112014023063A2 (pt) anticorpos que neutralizam rsv, mpv e pvm e usos dos mesmos
CL2011002994A1 (es) Construccion de proteina que comprende polipeptido casb7439; composicion inmunogenica que comprende dicha construccion; uso de la composicion porque sirve para inducir respuesta inmunitaria al casb7439 en un animal.
BR112018073205A2 (pt) método de microdiluição em caldo para avaliação e determinação da concentração inibitória mínima de polipeptídeos antibacterianos
TW200619228A (en) Immunogenic compositions of staphylococcus epidermidis polypeptide antigens

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: PARA QUE A PETICAO NO 20090072588/RJ DE 28.07.09 SEJA ATENDIDA, APRESENTAR PROCURACAO ORIGINAL, OUCOPIA AUTENTICADA, DANDO PODERES PARA DESISTIR DO PEDIDO.

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECIDA A PETICAO NO 020090072588/RJ DE 28.07.09, EM VIRTUDE DO DISPOSTO NO ARTIGO 219 INCISOII DA LPI.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.